Potential Response Predictors to IMV's Lead Compound in the DeCidE Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting
Stock Information for IMV Inc.
Loading
Please wait while we load your information from QuoteMedia.